Development of novel therapeutics targeting the blood–brain barrier: from barrier to carrier

J Li, M Zheng, O Shimoni, WA Banks, AI Bush… - Advanced …, 2021 - Wiley Online Library
The blood–brain barrier (BBB) is a highly specialized neurovascular unit, initially described
as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from …

Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects

J Chun, G Giovannoni, SF Hunter - Drugs, 2021 - Springer
Lysophospholipids are a class of bioactive lipid molecules that produce their effects through
various G protein-coupled receptors (GPCRs). Sphingosine 1-phosphate (S1P) is perhaps …

Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury

Y Zhou, A Shao, Y Yao, S Tu, Y Deng… - Cell Communication and …, 2020 - Springer
Traumatic brain injury (TBI) is one of the leading causes of fatality and disability worldwide.
Despite its high prevalence, effective treatment strategies for TBI are limited. Traumatic brain …

TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice

Y Cheng, S Desse, A Martinez, RJ Worthen… - Brain, behavior, and …, 2018 - Elsevier
Recovery from major depressive disorder is difficult, particularly in patients who are
refractory to antidepressant treatments. To examine factors that regulate recovery, we …

Sphingosine‐1‐phosphate signaling in immune cells and inflammation: roles and therapeutic potential

M Aoki, H Aoki, R Ramanathan, NC Hait… - Mediators of …, 2016 - Wiley Online Library
Sphingosine‐1‐phosphate (S1P) is a bioactive sphingolipid metabolite involved in many
critical cell processes. It is produced by the phosphorylation of sphingosine by sphingosine …

Angiogenesis and blood-brain barrier permeability in vascular remodeling after stroke

Y Yang, MT Torbey - Current neuropharmacology, 2020 - ingentaconnect.com
Angiogenesis, the growth of new blood vessels, is a natural defense mechanism helping to
restore oxygen and nutrient supply to the affected brain tissue following an ischemic stroke …

Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation

HC Tsai, MH Han - Drugs, 2016 - Springer
Abstract Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are ubiquitously
expressed. S1P-S1PR signaling has been well characterized in immune trafficking and …

Sphingosine 1-phosphate receptor modulators for multiple sclerosis

R Roy, AA Alotaibi, MS Freedman - CNS drugs, 2021 - Springer
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …

Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases

B Gril, AN Paranjape, S Woditschka, E Hua… - Nature …, 2018 - nature.com
Brain metastases are devastating complications of cancer. The blood–brain barrier (BBB),
which protects the normal brain, morphs into an inadequately characterized blood–tumor …

The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis

SL Cohan, RHB Benedict, BAC Cree, J DeLuca… - CNS drugs, 2022 - Springer
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5)
modulator approved in the United States and the European Union as an oral treatment for …